Martin Marino Buys 115,000 Shares of Microbix Biosystems (TSE:MBX) Stock

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino acquired 115,000 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were bought at an average price of C$0.28 per share, with a total value of C$32,200.00. Following the completion of the transaction, the director directly owned 2,000,167 shares of the company’s stock, valued at approximately C$560,046.76. The trade was a 6.10% increase in their ownership of the stock.

Martin Marino also recently made the following trade(s):

• On Tuesday, May 26th, Martin Marino acquired 69,000 shares of Microbix Biosystems stock. The shares were bought at an average price of C$0.26 per share, with a total value of C$17,940.00.
• On Wednesday, May 27th, Martin Marino acquired 24,500 shares of Microbix Biosystems stock. The shares were bought at an average price of C$0.26 per share, with a total value of C$6,370.00.

Microbix Biosystems Stock Performance

MBX stock traded down C$0.01 during mid-day trading on Thursday, hitting C$0.28. 190,765 shares of the company were exchanged, compared to its average volume of 62,796. The business has a 50 day simple moving average of C$0.24 and a 200-day simple moving average of C$0.24. The company has a current ratio of 5.35, a quick ratio of 5.57 and a debt-to-equity ratio of 27.03. The stock has a market capitalization of C$37.81 million, a PE ratio of -6.71 and a beta of 0.48. Microbix Biosystems Inc. has a 1-year low of C$0.21 and a 1-year high of C$0.34.

Microbix Biosystems (TSE:MBX) last issued its quarterly earnings data on Thursday, May 14th. The company reported C($0.01) earnings per share (EPS) for the quarter. The company had revenue of C$3.38 million for the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%. On average, equities analysts forecast that Microbix Biosystems Inc. will post 0.02 earnings per share for the current year.

About Microbix Biosystems

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.